CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues:
Obstructive sleep apnea (OSA) - related	$ 524,172	$ 564,117
Total revenues	524,172	564,117
Costs and expenses:
Costs of revenues	261,170	286,332
Selling, general and administrative	1,745,094	4,708,930
Depreciation and amortization	599	598
Total costs and expenses	2,006,863	4,995,860
Operating loss	(1,482,691)	(4,431,743)
Other income (expense):
Interest expense	(1,436,974)	(1,441,583)
Legal settlement (See Note 15)	215,848	(17,031)
Setttlement of prior accounting services	(240,000)
Extinguishment of loan due to shareholder	7,771,140
Tax penalty	(50)
Other income	2,380
Total other income (expense)	6,312,344	(1,458,614)
Net income (loss)	$ 4,829,653	$ (5,890,357)
PER SHARE INFORMATION
Basic	$ 0.07	$ (0.09)
Weighted average number of common shares outstanding	65,362,240	63,063,685